Ignyta (RXDX) Got Lower Jefferies Rating And $27.0 Target; Sandler Capital Management Decreased By $2.56 Million Its Healthcare Tr Amer (HTA) Stake

Sandler Capital Management decreased Healthcare Tr Amer Inc (HTA) stake by 78.94% reported in 2017Q3 SEC filing. Sandler Capital Management sold 88,268 shares as Healthcare Tr Amer Inc (HTA)’s stock rose 2.01%. The Sandler Capital Management holds 23,550 shares with $702,000 value, down from 111,818 last quarter. Healthcare Tr Amer Inc now has $6.24 billion valuation. The stock increased 0.40% or $0.12 during the last trading session, reaching $29.86. About 183,349 shares traded. Healthcare Trust of America, Inc. (NYSE:HTA) has risen 7.80% since December 22, 2016 and is uptrending. It has underperformed by 8.90% the S&P500.

Among 9 analysts covering Ignyta (NASDAQ:RXDX), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ignyta has $38 highest and $1500 lowest target. $23.88’s average target is -10.81% below currents $26.775 stock price. Ignyta had 17 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by JP Morgan on Thursday, October 12 with “Overweight”. JP Morgan initiated the shares of RXDX in report on Thursday, June 23 with “Overweight” rating. Cantor Fitzgerald maintained Ignyta, Inc. (NASDAQ:RXDX) rating on Sunday, June 4. Cantor Fitzgerald has “Buy” rating and $1500 target. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The stock has “Buy” rating by Cantor Fitzgerald on Monday, July 10. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 15. The firm has “Overweight” rating given on Wednesday, August 12 by Piper Jaffray. On Friday, October 23 the stock rating was initiated by Jefferies with “Buy”. The firm earned “Buy” rating on Monday, October 26 by Cantor Fitzgerald. SunTrust initiated the shares of RXDX in report on Tuesday, November 21 with “Buy” rating.

Analysts await Healthcare Trust of America, Inc. (NYSE:HTA) to report earnings on February, 21. They expect $0.42 earnings per share, 0.00% or $0.00 from last year’s $0.42 per share. HTA’s profit will be $87.77 million for 17.77 P/E if the $0.42 EPS becomes a reality. After $0.42 actual earnings per share reported by Healthcare Trust of America, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 12 analysts covering Healthcare Trust of America (NYSE:HTA), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Healthcare Trust of America had 32 analyst reports since August 26, 2015 according to SRatingsIntel. As per Wednesday, January 4, the company rating was upgraded by Mizuho. The firm earned “Outperform” rating on Tuesday, June 20 by BMO Capital Markets. The stock of Healthcare Trust of America, Inc. (NYSE:HTA) has “Buy” rating given on Tuesday, July 18 by BMO Capital Markets. The firm has “Buy” rating by Jefferies given on Friday, July 7. Raymond James upgraded Healthcare Trust of America, Inc. (NYSE:HTA) on Monday, July 17 to “Strong Buy” rating. As per Wednesday, December 9, the company rating was initiated by Morgan Stanley. Stifel Nicolaus maintained Healthcare Trust of America, Inc. (NYSE:HTA) on Tuesday, July 4 with “Buy” rating. The firm earned “Buy” rating on Monday, March 21 by SunTrust. BMO Capital Markets maintained Healthcare Trust of America, Inc. (NYSE:HTA) rating on Monday, October 2. BMO Capital Markets has “Buy” rating and $35.0 target. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, July 12.

Sandler Capital Management increased Capital One Finl Corp (Put) (NYSE:COF) stake by 117,200 shares to 194,700 valued at $16.48M in 2017Q3. It also upped Teck Resources Ltd (NYSE:TCK) stake by 24,700 shares and now owns 71,800 shares. Waste Connections Inc was raised too.

The stock increased 72.19% or $11.225 during the last trading session, reaching $26.775. About 25.70M shares traded or 2011.57% up from the average. Ignyta, Inc. (NASDAQ:RXDX) has risen 14.24% since December 22, 2016 and is uptrending. It has underperformed by 2.46% the S&P500.

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. The company has market cap of $1.78 billion. The Company’s products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. It currently has negative earnings.